Orbicular Company Profile
What is the competitive landscape for ORBICULAR
ORBICULAR has four approved drugs.
Summary for Orbicular
| US Patents: | 0 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 4 |
| Patent Litigation for Orbicular: | See patent lawsuits for Orbicular |
Drugs and US Patents for Orbicular
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orbicular | LIRAGLUTIDE | liraglutide | SOLUTION;SUBCUTANEOUS | 217590-001 | Jan 14, 2026 | AP1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Orbicular | LIRAGLUTIDE | liraglutide | SOLUTION;SUBCUTANEOUS | 217234-001 | Feb 24, 2026 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Orbicular Pharm Tech | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | hydrocortisone; neomycin sulfate; polymyxin b sulfate | SOLUTION/DROPS;OTIC | 220938-001 | Aug 27, 2026 | AT | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
